Conserved type I IFN signalling in PLD4-deficient models supports the translational applicability of JAK inhibitor, although interspecies discrepancies necessitate clinical validation in patients with PLD4 deficiency. This evidence concerns the gene PLD4 and hyperinsulinemic hypoglycemia, familial, 4.